Connect with us

General Health

DNA SEQUENCING Market is anticipated to reach $25,470 million by 2025 | Abbott Laboratories, Agilent Technologies, Danaher Corporation

Published

on

DNA SEQUENCING Market
Press Release

The ‘ DNA SEQUENCING market’ research report added by Report Ocean, is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, DNA SEQUENCING market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, DNA SEQUENCING market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

The global DNA sequencing market accounted for $6,243 million in 2017, and is anticipated to reach $25,470 million by 2025, registering a CAGR of 19.0% from 2017 to 2025.

 UPTO 30% OFF ON SINGLE USER PDF: https://www.reportocean.com/industry-verticals/sample-request?report_id=27308

 DNA SEQUENCING Market: Competitive Analysis by Key Players:

Abbott Laboratories
Agilent Technologies, Inc.
Danaher Corporation (Beckman Coulter, Inc.)
F. Hoffmann-La Roche Ltd
Illumina, Inc
LI-COR Biosciences, Inc.
Pacific Biosciences of California, Inc.
SIEMENS AG; PerkinElmer Inc.
Thermo Fisher Scientific, Inc.

The Global DNA SEQUENCING Market also explains the competitive landscape among the major key players of the market, based on various parameters, such as:

  • News Feed Analysis of the Global DNA SEQUENCING Market players
  • Key Players Ranking Analysis of the Global DNA SEQUENCING Market
  • Positioning Matrix of the Global DNA SEQUENCING Market
  • Others

 DNA SEQUENCING Market Segments:

By Product (Consumable, Instrument, and Service)

By Application (Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, and Other Applications),

By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real-Time Sequencing, Chain Termination Sequencing, and Nanopore Sequencing),

By End User (Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics)

 DNA SEQUENCING Market: Insights

DNA sequencing is a molecular technique that helps determine the nucleotide sequence of DNA (deoxyribonucleic acid), which is the most fundamental level of knowledge of a gene or genome. The global DNA sequencing market accounted for $6,243 million in 2017, and is anticipated to reach $25,470 million by 2025, registering a CAGR of 19.0% from 2017 to 2025. DNA sequencing has revolutionized molecular biology and genomics research. The knowledge of DNA sequences of genes and other parts of the genome of organisms has become essential for life-science research and also in applied fields, such as forensics, cancer diagnostics, and others. Through this method, billions of DNA strands can be sequenced efficiently. DNA sequencing has made it possible to conveniently sequence whole genomes and analyze various DNA-protein interactions. This technique allows the researcher to focus, study, and interpret deep sequence target regions. They are utilized through varied interventions, such as oncology, biomarker studies, drug discovery, understanding reproductive health, and personalized genomics.

Technological advancements in sequencing equipment, surge in applications of DNA sequencing, and increase in genome mapping programs drive the global DNA sequencing market. In addition, rise in awareness pertaining to DNA sequencing and increase in investment in research, development, and innovation supplement the market growth. However, lack of skilled professionals, ethical & legal limitations related to DNA sequencing, and standardization concerns in sequencing procedures impede the market growth. Furthermore, use of cloud computing as a potential data management service and the untapped emerging countries offer lucrative opportunities for the market players.
The DNA sequencing market is segmented based on product, application, technology, end user, and geography. Based on product, it is categorized into consumable, instrument, and service. The consumables segment accounted for a dominant share in 2017 and is expected to maintain this trend during the forecast period. This is attributed to the fact that they are widely used throughout the sample preparation process and other pre-requisite steps of DNA sequencing.

Get a Sample Report for more Expert and Official insights: @ https://www.reportocean.com/industry-verticals/sample-request?report_id=27308

Furthermore, the years considered for the study are as follows:

Historical year – 2013-2017

Base year – 2018

Forecast period** – 2019 to 2025 [** unless otherwise stated]

Regional Analysis:

The market research study offers in-depth regional analysis along with the current market scenarios. The major regions analyzed in the study are:

  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific

Key highlights and important features of the Report:

Overview and highlights of product and application segments of the global DNA SEQUENCING Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Explore about Sales data of key players of the global DNA SEQUENCING Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the DNA SEQUENCING Market.

Explore about gross margin, sales, revenue, production, market share, CAGR, and market size by region.

Describe DNA SEQUENCING Market Findings and Conclusion, Appendix, methodology and data source;

Research Methodology:

The market research was done by adopting various tools under the category of primary and secondary research. For primary research, experts and major sources of information have been interviewed from suppliers’ side and industries, to obtain and verify the data related to the study of the Global DNA SEQUENCING Market. In secondary research methodology, various secondary sources were referred to collect and identify extensive piece of information, such as paid databases, directories and annual reports and databases for commercial study of the Global DNA SEQUENCING Market. Moreover, other secondary sources include studying technical papers, news releases, government websites, product literatures, white papers, and other literatures to research the market in detail.

Browse Premium Research Report with Tables and Figures at @ https://www.reportocean.com/industry-verticals/details?report_id=27308

There are 15 Chapters to display the Global DNA SEQUENCING Market:

Chapter 1, to describe Definition, Specifications and Classification of Global DNA SEQUENCING, Applications of , Market Segment by Regions;
Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;
Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of , Capacity and Commercial Production Date, Manufacturing Plants Distribution, Export & Import, R&D Status and Technology Source, Raw Materials Sources Analysis;
Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);
Chapter 5 and 6, to show the Regional Market Analysis that includes United States, EU, Japan, China, India & Southeast Asia, Segment Market Analysis (by Type);
Chapter 7 and 8, to explore the Market Analysis by Application Major Manufacturers Analysis;
Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;
Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;
Chapter 11, to analyze the Consumers Analysis of Global DNA SEQUENCING by region, type and application;
Chapter 12, to describe DNA SEQUENCING Research Findings and Conclusion, Appendix, methodology and data source;
Chapter 13, 14 and 15, to describe DNA SEQUENCING sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Name: Varda

Email: [email protected]

Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 – India

Tel: +1 888 212 3539 (US – TOLL FREE)

Website: https://www.reportocean.com/

This post was originally published on Health News Office

General Health

Gene Therapy Market Growth Set to Surge Significantly during 2018 to 2026

Published

on

Press Release

Transparency Market Research (TMR) has published a new report titled, “Gene Therapy Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global gene therapy market was valued at US$ 17.0 Mn in 2017 and is projected to expand at a CAGR of 40.0% from 2018 to 2026. New product approvals, promising therapeutic outcomes of gene therapy, and high prevalence of non-Hodgkin Lymphoma are anticipated to drive the global market in the next few years. Europe is projected to dominate the global gene therapy market, followed by U.S., by the end of 2026.

Potential unmet needs in the fields of oncology, rare genetic disorders in the U.S. and Europe, new product approvals and commercialization, and high clinical R&D budgets are likely to drive the gene therapy market in these regions during the forecast period. The gene therapy market in Rest of World is projected to expand at a significant CAGR during the forecast period. The high growth rate is attributed to the anticipated approval and commercialization of gene therapy products in developed countries such as Japan, Australia & New Zealand, GCC countries, and China, and high prevalence of non-Hodgkin Lymphoma and head and neck cancers.

New product approvals & commercialization drives market

2016, 2017, and 2018 were key milestones in the history of the gene therapy market in the U.S. and Europe, as around four gene therapy products have been approved and commercialized. These products are currently in the infancy stage of commercialization, and have exhibited highly positive therapeutic outcomes. For instance, in May 2016, GlaxoSmithKline (GSK) gene therapy product, Strimvelis, received marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID. Furthermore, in August 2017, the USFDA approved Novartis AG’s flagship gene therapy product, Kymriah, for the treatment of children and adults up to the age of 25 years affected with B-cell precursor acute lymphoblastic leukemia (ALL). Thus, recent approvals of gene therapy products in the U.S. and Europe for the treatment of various life threatening disorders is projected to fuel the gene therapy market during the forecast period.

Request to View Sample of Report  https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1838

Yescarta to be highest revenue generating gene therapy product

The report offers a detailed segmentation of the global gene therapy market based on different gene therapy products approved and commercialized. Based on product, the global gene therapy market has been segmented into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. Yescarta (Axicabtagene Ciloleucel) is a genetically modified autologous Chimeric Antigen Receptor T (CAR T) cell immunotherapy developed by Gilead Sciences, Inc. for the treatment of adult patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL).

It is the first CAR T therapy approved by the US FDA for the treatment of DLBCL. The Yescarta segment is projected to dominate the global gene therapy market by the end of 2026. Anticipated commercialization of Yescarta in Europe and other developed countries and increasing number of treatment centers are key factors that are likely to lead to the dominant share held by Yescarta by the end of 2026.

Request PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1838

Oncology segment to account for high market share

In terms of application, the global gene therapy market has been segmented into ophthalmology, oncology, and adenosine deaminase ?deficient severe combined immunodeficiency (ADA-SCID). The oncology segment is likely to account for a significant share of the market by the end of 2026. Oncology is a highly studied medical field in the clinical pipeline studies of gene therapy candidates. More than 60% of gene therapy clinical research studies are focused on oncology. The large share held by the oncology segment is attributed to the approval and commercialization of Yescarta and Kymriah, in the last one to two years, for the treatment of certain types of non-Hodgkin lymphoma in the U.S. and Europe. Furthermore, increase in demand for Gendicine in China for the treatment of head and neck cancers is projected to drive the segment during the forecast period.

Request For Discount On This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1838

Europe offers high incremental opportunity

The gene therapy market in Europe is projected to expand at a significant CAGR of 30.6% during the forecast period. Large number of patient population with refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), promising therapeutic outcomes, rising demand for gene therapy treatment, and increasing number of gene therapy treatment centers in Europe are key factors that are likely to fuel the gene therapy market in Europe. Moreover, different pricing models are being evaluated by payers and governments to enable access to high priced gene therapy products. This is likely to drive the demand for gene therapy products in Europe during the forecast period.

Large number of clinical pipeline studies and significant investments in gene therapy to gain the first mover advantage

The global gene therapy market is highly consolidated, with very few global players accounting for a major share. Currently, only five companies; Gilead life Sciences Inc. Spark Therapeutic Inc., Novartis AG, Sibiono GeneTech Co. Ltd, and Orchard Therapeutics Limited offer gene therapy products in the market. Most biopharmaceutical companies have invested significantly in clinical R&D for the development of gene therapy products for different chronic and genetic disorders. Large number of gene therapy products are under different stages of clinical pipeline studies, and the number of gene therapy candidates is projected to rise consistently during the forecast period. For instance, according to the Journal of Gene Medicine, there were around 2,597 gene therapy candidates under clinical trials, as of 2017. Of the total clinical studies, around 65% of studies were focused on oncology, 11% of studies were focused on monogenetic field, 7% on infectious diseases and cardiovascular disease, each.

This post was originally published on Health News Office

Continue Reading

General Health

Drug Eluting Balloon Market is Booming Worldwide According to New Research Report

Published

on

Press Release

Transparency Market Research (TMR) has published a new report titled, “Drug Eluting Balloon Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global drug eluting balloon market was valued at US$ 420 Mn in 2017 and is expected to reach US$ 1800 Mn in 2026, expanding at a CAGR of around 18% from 2018 to 2026. The global drug eluting balloon market is anticipated to witness relatively stable growth owing to approvals of expected pipeline of drug eluting balloon and introduction of novel drug eluting balloon-based treatment approaches.

High prevalence of cardiovascular diseases among geriatric population due to adulterated food, booming research & development in treatment of cardiovascular diseases, and developed health care infrastructure are expected to fuel the growth of the global drug eluting balloon market during the forecast period. North America is expected to account for a major share of the global drug eluting balloon market during the forecast period owing to strong presence of major players with established distribution networks in the region. The drug eluting balloon market in Asia Pacific is likely to expand at a significant CAGR from 2018 to 2026.

Request to View Sample of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

Cardiovascular diseases are a major threat to public health. Peripheral artery disease (PAD) is a common form of peripheral vascular disease, predominantly found among people above 65 years of years. PAD narrows the walls of arteries and limits the speed of blood flow. It can also affect the arteries which carry blood from the head to heart, kidneys, and stomach, although it more commonly affects the peripheral areas. Considering the increase in incidence of cardiovascular diseases, it is important to understand the factors influencing the severity of the diseases and the best possible treatment options for them. Various public and private players are striving to reduce the prevalence cardiovascular disease. In the developed countries, physicians and governments have begun to educate the general population about PAD. In the U.S., doctors, health care providers, payers, and medical devices companies celebrate ‘PAD Awareness Month’ in September each year.

During ‘PAD Awareness Month’, they try to educate people about the after-effects of PAD and their treatment procedures. Several agencies are providing funds to research organizations to promote the development of drug eluting balloon that are more effective in the treatment of cardiovascular diseases. This is likely to drive the global drug eluting balloon market during the forecast period.

Request PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2321

In terms of product, the global drug eluting balloon market has been classified into peripheral drug eluting balloon, coronary drug eluting balloon, and others. The peripheral drug eluting balloon segment is likely to account for a major share of the global market during the forecast period. The segment is projected to expand at a steady pace, owing to promising effective and efficient drug eluting balloon in the pipeline for addressing better treatment options for advanced medical approaches. The drug eluting balloon market is witnessing a shift toward priority development of new drug eluting balloon for treatment of diseases other than cardiovascular disease. The other drug eluting balloon segment is expected to grow rapidly during the forecast period.

Based on drug coating technology, the global drug eluting balloon market has been divided into FreePac, Paccocath, TransPax, EnduraCoat, and others. The FreePac segment is projected to dominate the global drug eluting market owing to the predominant presence of the technology in the global drug eluting balloon market. The segment is anticipated to grow at an average rate in the near future due to emergence of new drug coating technologies in the market. The TransPax segment is estimated to expand at the highest CAGR during the forecast period. Based on end-user, the global drug eluting balloon market has been segmented into hospitals and ambulatory surgical centers, CATH labs, and others. Hospitals and ambulatory surgical centers is expected to propel the global drug eluting balloon market during the forecast period.

Request For Discount On This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2321

North America and Europe accounted for more than 65% share of the global drug eluting balloon market in 2017, owing to high health care expenditure, high rate of diagnosis and treatment of cardiovascular diseases (coronary artery diseases, peripheral artery diseases, etc.), rise in awareness regarding drug eluting balloon, greater market penetration of newly developed advanced drug eluting balloon products, favorable reimbursement policies assuring investment returns for new market entrants, and presence of major market players in the regions. However, expiry of TPT reimbursement on drug eluting balloon in December 2017 and stringent regulatory framework of the U.S. are likely to hamper the growth of the drug eluting balloon market in North America in next two to three years. Asia Pacific is likely to offer significant opportunities to the drug eluting balloon market during the forecast period owing to growth in geriatric population, demand for better quality of care, and rise in incidence of cardiovascular diseases in the region.

The global drug eluting balloon market is dominated by a few major players, accounting for approximately 70% share of the market. Technological advancements, evaluation of safety and efficacy of drug eluting balloon, and increased per capita income are boosting buyer power in terms of opting for advanced medical procedures. These key players are projected to dominate the global market, owing to their strong pipeline focus and established distribution network. The report profiles leading players operating in the global drug eluting balloon market, for example, Medtronic, Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc, and Biotronik,.

This post was originally published on Health News Office

Continue Reading

General Health

Heart Valve Devices Market “Estimated to Reach US$16.2 Billion by 2025” Detailed in new Research Report

Published

on

Press Release

As per Transparency Market Research, the global Heart Valve Devices Market will likely register a CAGR of 12.4% during the period from 2017 to 2025. Rising at this pace, the market which was worth US$5.8 bn in 2016 will likely become worth US$16.2 bn in 2025.

Majorly fuelling growth in the global market for heart valve devices market is the increasing instances of obesity and unhealthy lifestyle causing various cardiac diseases and pathological disorders. In addition, the increasing demand for minimally invasive procedures and continued product modifications by leveraging the latest technologies developments have brought about more effective heart valve devices. This has also had a positive impact on the market.

Request to View Sample of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=486

This era of technological advancements has immensely changed the ways of living and has increased various health concerns. Heart valve disease is one health related concern that have increased largely in past few years. As per the study conducted by American Heart Association (AHA) reveals that more than a million people in America have established moderate or severe heart valve disease. The increasing prevalence of heart valve disease is seen due to persistence level of stress, sedentary lifestyle, irregular sleeping habits, and increasing number of geriatric population. In case a person diagnosed with heart valve disease can experience failure of a single or multiple valves. The most common valve to get affected are mitral and aortic valves. Technologically advanced devices used in replacement of transcatheter valve or transcatheter aortic valve are significantly increasing in the market. Furthermore, growing heart related disease and technological innovations to solve this have grown the market for heart valve devices globally.

Request PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=486

Recently, Abbott Laboratories has its clearance to work on next version of MitraClip heart valve repair device, a next generation device from the U.S. Food and Drug Administration (FDA). It is used to repair leaky mitral valve without an open-heart surgery. Technological innovation has improved the transcatheter clip based therapy and have treated thousands of people across the world in last ten years. The MitraClip system is efficient in providing navigation and positioning abilities with advanced steering that will help in treating difficult anatomies for cardiologist. The use of these advanced devices to be placed during placement and making the procedure more accurate. These innovations in heart valve diseases device will grow the market and benefit the patients in longer run.

Request For Discount On This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=486

Some of the prominent trends in the heart valve disease market are:

Nowadays, availability heart valve devices has grown vastly which includes transcatheter heart valves, mechanical heart valves, and biological heart valves. Among these transcatheter heart valves and mechanical heart valves are experiencing growing demand in various economies.

Transcatheter heart valve devices are having higher demand in the market due to superior technology in developed nations. The demand for transcatheter heart valve devices is also growing because of lower mortality rate achieved by them and more than average selling price of the device.

Browse Press Release – https://www.transparencymarketresearch.com/pressrelease/heart-valve-devices-market.htm

The soaring requirement for minimally invasive procedures, which leads to shorter stays at the hospital and accelerate the healing duration are also increasing the demand for heart valve devices. The hearty valve devices are compact and require minimally invasive surgeries that are high in demand nowadays will further increase the market.

North America is leading the market for global heart valve devices owing to advanced technology at average selling price. High geriatric population suspetable of varfious heart disease, government supportive healthcare facilities, and availability of various heart supportive devices have made these regions lead the market. Additionally, increasing awareness among the developing economies is also increasing the demand for heart valve devices market.

This post was originally published on Health News Office

Continue Reading

Trending